📣 VC round data is live. Check it out!

Anatolia Geneworks Valuation Multiples

Discover revenue and EBITDA valuation multiples for Anatolia Geneworks and similar public comparables like Envoy Medical, Sequana Medical, Svas Biosana, K Pharma and more.

Anatolia Geneworks Overview

About Anatolia Geneworks

Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi Ve Ticaret AS is an international biotechnology company. It is engaged in designing, developing, and manufacturing Real-Time PCR kits, nucleic acid extraction kits, and automated nucleic acid extraction instruments. It also manufactures NA Extraction kits, Microbiology kits, Genetic Disorders kits, Panel kits, Sequencing kits, Food Testing kits.


Founded

2010

HQ

Turkey

Employees

N/A

Financials (FY)

Revenue: $16M
EBITDA: ($2M)

EV

$62M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Anatolia Geneworks Financials

Anatolia Geneworks reported last fiscal year revenue of $16M and negative EBITDA of ($2M).

In the same fiscal year, Anatolia Geneworks generated $10M in gross profit, ($2M) in EBITDA losses, and had net loss of ($7M).


Anatolia Geneworks P&L

In the most recent fiscal year, Anatolia Geneworks reported revenue of $16M and EBITDA of ($2M).

Anatolia Geneworks is unprofitable as of last fiscal year, with gross margin of 64%, EBITDA margin of (13%), and net margin of (42%).

See analyst estimates for Anatolia Geneworks
Last FY202320242025202620272028
Revenue$16M$5M$12M$16M
Gross Profit$10M$4M$7M$10M
Gross Margin64%80%63%64%
EBITDA($2M)($2M)($1M)($2M)
EBITDA Margin(13%)(34%)(11%)(13%)
EBIT Margin(7%)(19%)3%(7%)
Net Profit($7M)($3M)($5M)($7M)
Net Margin(42%)(57%)(41%)(42%)
Net Debt$4M---

Financial data powered by Morningstar, Inc.

Anatolia Geneworks Stock Performance

Anatolia Geneworks has current market cap of $55M, and enterprise value of $62M.

Market Cap Evolution


Anatolia Geneworks' stock price is $0.25.

Anatolia Geneworks share price increased by 2.4% in the last 30 days, and by 9.0% in the last year.

Anatolia Geneworks has an EPS (earnings per share) of $-0.03.

See more trading valuation data for Anatolia Geneworks
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$62M$55M1.5%2.4%8.4%9.0%$-0.03

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Anatolia Geneworks Valuation Multiples

Anatolia Geneworks trades at 3.9x EV/Revenue multiple, and (28.7x) EV/EBITDA.

See NTM and 2027E valuation multiples for Anatolia Geneworks

Anatolia Geneworks Financial Valuation Multiples

As of June 3, 2026, Anatolia Geneworks has market cap of $55M and EV of $62M.

Anatolia Geneworks has a P/E ratio of (8.0x).

Last FY202320242025202620272028
EV/Revenue3.9x12.0x5.4x3.9x
EV/EBITDA(28.7x)(35.4x)(51.2x)(28.7x)
EV/EBIT(54.1x)(64.8x)165.1x(54.1x)
EV/Gross Profit6.1x15.1x8.6x6.1x
P/E(8.0x)(18.3x)(11.4x)(8.0x)
EV/FCF(15.4x)n/m(27.3x)(15.4x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Anatolia Geneworks Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Anatolia Geneworks Margins & Growth Rates

In the most recent fiscal year, Anatolia Geneworks reported gross margin of 64%, EBITDA margin of (13%), and net margin of (42%).

See estimated margins and future growth rates for Anatolia Geneworks

Anatolia Geneworks Margins

Last FY20242025202720282029
Gross Margin64%63%64%
EBITDA Margin(13%)(11%)(13%)
EBIT Margin(7%)3%(7%)
Net Margin(42%)(41%)(42%)
FCF Margin(25%)(20%)(25%)

Anatolia Geneworks Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth122%40%
Gross Profit Growth76%40%
EBITDA Growth(31%)78%
EBIT Growth(139%)(405%)
Net Profit Growth60%43%
FCF Growth(2458%)77%

Data powered by FactSet, Inc. and Morningstar, Inc.

Anatolia Geneworks Operational KPIs

Access forward-looking KPIs for Anatolia Geneworks
Last FY202320242025202620272028
S&M Expenses to Revenue13%10%10%13%
G&A Expenses to Revenue8%11%5%8%
R&D Expenses to Revenue0%4%1%0%
Opex to Revenue71%98%60%71%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Anatolia Geneworks Competitors

Anatolia Geneworks competitors include Envoy Medical, Sequana Medical, Svas Biosana, K Pharma, Singular Health, Bactiguard, SciBase Holding, Nortech Systems, Daxor and HeartBeam.

Most Anatolia Geneworks public comparables operate across Laboratory Services, Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Envoy Medical123.8x133.4x(1.4x)-
Sequana Medical775.8x28.9x(2.0x)(4.0x)
Svas Biosana0.7x0.7x5.4x5.5x
K Pharma--(7.0x)-
Singular Health288.8x-(9.6x)-
Bactiguard3.0x3.1x15.0x18.6x
SciBase Holding10.2x8.1x(5.0x)(5.5x)
Nortech Systems0.6x-28.8x-

This data is available for Pro users. Sign up to see all Anatolia Geneworks competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Anatolia Geneworks

When was Anatolia Geneworks founded?Anatolia Geneworks was founded in 2010.
Where is Anatolia Geneworks headquartered?Anatolia Geneworks is headquartered in Turkey.
Is Anatolia Geneworks publicly listed?Yes, Anatolia Geneworks is a public company listed on Borsa Istanbul.
What is the stock symbol of Anatolia Geneworks?Anatolia Geneworks trades under ANGEN ticker.
When did Anatolia Geneworks go public?Anatolia Geneworks went public in 2021.
Who are competitors of Anatolia Geneworks?Anatolia Geneworks main competitors include Envoy Medical, Sequana Medical, Svas Biosana, K Pharma, Singular Health, Bactiguard, SciBase Holding, Nortech Systems, Daxor, HeartBeam.
What is the current market cap of Anatolia Geneworks?Anatolia Geneworks' current market cap is $55M.
What is the current revenue of Anatolia Geneworks?Anatolia Geneworks' last fiscal year revenue is $16M.
What is the current EV/Revenue multiple of Anatolia Geneworks?Current revenue multiple of Anatolia Geneworks is 3.9x.
Is Anatolia Geneworks profitable?No, Anatolia Geneworks is not profitable.
How many companies Anatolia Geneworks has acquired to date?Anatolia Geneworks hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Anatolia Geneworks has invested to date?Anatolia Geneworks hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Anatolia Geneworks

Lists including Anatolia Geneworks

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial